Joined: 12/6/2011
Posts: 3326
|
From Alzheimer's Daily News:
(Source: J & J) - Janssen Alzheimer Immunotherapy, a subsidiary of Johnson & Johnson, has decided to discontinue the development of bapineuzumab IV in mild-to-moderate Alzheimer's disease based on the co-primary clinical endpoints not being met in the Janssen AI-led Studies 301 and 302.
"While we are disappointed in the results of the two bapineuzumab IV studies, particularly in light of the urgent need for new advancements in Alzheimer's disease, we believe that targeting and clearing beta amyloid remains a promising path to potential clinical benefits for people suffering from this disease," said Dr. Husseini Manji.
Go to full story: http://www.jnj.com
|